GlassScriptPhysician profile
Hsingming J Liou
NPI 1770678377
$10,090.25
in general payments reported to CMS, 2019-2025
34 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2021: $1,065 · 2022: $868 · 2023: $1,926 · 2024: $2,449 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,525.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,061.78 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Genzyme Corporation | $853.26 | 2022-2025 | |
| Janssen Biotech, INC. | $819.99 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Novo Nordisk INC | $596.11 | 2023-2025 | Wegovy |
| Abbvie INC. | $491.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $430.40 | 2023-2024 | Invega, Invega Sustenna, Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.24 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $375.06 | 2022-2023 | Reblozyl |
| Amgen INC. | $364.87 | 2021-2025 | Amjevita |
| Takeda Pharmaceuticals U.S.A., INC. | $360.16 | 2021 | |
| Exelixis INC. | $342.86 | 2019-2023 | Cabometyx |
| Lilly USA, LLC | $330.34 | 2023-2024 | Olumiant, Retevmo |
| Fresenius Kabi USA, LLC | $268.49 | 2023-2025 | Kabiven, Stimufend |
| Bayer Healthcare Pharmaceuticals INC. | $261.39 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.95 | 2021-2023 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $248.64 | 2021-2023 | Calquence |
| Mirum Pharmaceuticals, INC. | $248.21 | 2025 | Livmarli |
| Gilead Sciences, INC. | $238.94 | 2022-2023 | |
| Eisai INC. | $237.53 | 2025 | |
| Biogen, INC. | $195.14 | 2021-2025 | Skyclarys |
| Neurocrine Biosciences, INC. | $170.80 | 2024 | Ingrezza |
| Dexcom, INC. | $151.06 | 2023 | Dexcom G7 Gss (161) |
| Shire North American Group INC | $142.54 | 2019 | |
| Kyowa Kirin, INC. | $137.20 | 2024 | Nourianz |
| Genentech USA, INC. | $125.14 | 2022 | |
| Ferring Pharmaceuticals INC. | $124.99 | 2022 | |
| Heron Therapeutics, INC. | $124.96 | 2021 | |
| Almirall LLC | $124.86 | 2024 | Klisyri |
| Astellas Pharma US INC | $124.71 | 2019 | |
| Mallinckrodt Hospital Products INC. | $119.16 | 2023 | Terlivaz |
| Dynavax Technologies Corporation | $117.16 | 2019 | |
| Shionogi INC | $113.94 | 2025 | Fetroja |
| Regeneron Healthcare Solutions, INC. | $92.15 | 2025 | Libtayo |
| Galderma Laboratories, L.P. | $24.95 | 2025 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsingming Liou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.